Trial Profile

Second pivotal study of sustained-exposure otic dexamethasone [OTO 104] in patients with Meniere's disease

Status: Planning

Phase of Trial: Phase II

Latest Information Update: 13 Mar 2018

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Dexamethasone (Primary)
Indications Meniere's disease
Focus Registrational; Therapeutic Use
Sponsors Otonomy [CEASED]

Most Recent Events

08 Mar 2018 According to an Otonomy media release, trial is expected to start in mid 2018.
09 Oct 2014 According to an Otonomy media release, OTO-104 has been granted Fast Track designation by the U.S. FDA.
12 Dec 2013 New trial record

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com